Abstract: Malignant cells thrive in a highly specialized, stromal environment, which harbors support cells, blood vessels, and diverse leukocyte populations. There is increasing evidence that "by default", intratumoral inflammation fosters angiogenic and vasculogenic processes and simultaneously creates an immunosuppressive micromilieu. This self-amplifying loop of proangiogenic inflammation represents a serious obstacle for adaptive anticancer immune responses. However, angiogenesis is a highly dynamic process, which can be reversed in the "right" inflammatory context; this in turn facilitates immune effector cell entry and tumor rejection. Thus, we propose that a shift from proangiogenic to antiangiogenic inflammation creates a tumor environment permissive for immune destruction. This is a new concept, which integrates antiangiogenic and immune therapeutic treatment modalities. J. Leukoc. Biol. 80: 685-690; 2006.
INTRODUCTION
This review focuses on the dynamics of neovascularization in the context of intratumoral inflammation. Our goal is to discuss the proangiogenic effects of different stromal constituents within the tumor microenvironment, which act in concert to promote local tumor progression. These stromal constituents can be viewed as contributors to the process of inflammation and include fibroblasts and endothelial cells, as well as adaptive and innate immune effector cells. However, we present the argument that the presence of these inflammatory components can be beneficial and specifically targeted, such that the proangiogenic process can be reversed. This reversal supports enhanced immune cell function within solid tumors. The mechanisms underlying these processes are complex and multifactorial, and our understanding is still in its infancy. Thus, our discussion focuses on selected cytokines/chemokines, which have been shown to exert dual effects on the tumor vasculature and infiltrating effector cells to promote tumor rejection.
INFLAMMATION PROMOTES ANGIOGENESIS
Neovascularization is a fundamental process, which regulates metabolic supply to tissues in numerous physiological and pathological situations. During physiological angiogenesis, new vessels arise, mature, and assemble into a hierarchical, vascular network in a tightly controlled, self-limiting process. During normal wound-healing, inflammatory cells are activated rapidly and facilitate the formation of granulation tissue, stromal remodeling, and growth of neovessels. Subsequently, in the final phase of the healing process, inflammation resolves, and proliferative activities are terminated [1] . In contrast, in a tumor scenario, exposure to proangiogenic growth factors leads to ongoing vascular remodeling and a chaotic network of proliferating tumor vessels [2] . Rightly, tumors are described as wounds that never heal [3] ; thus, the tumor microenvironment can be described as one in which there is ongoing inflammation. This intratumoral inflammation plays a major role in promoting progressive tumor growth and angiogenesis [1, 4] . Although it is clear that tumor cells produce key angiogenic factors such as vascular endothelial growth factor (VEGF), which can initiate angiogenesis in a quiescent vasculature [5] , we now understand that local inflammatory cells, such as macrophages and granulocytes, secrete a wealth of cytokines and chemokines, which also affect endothelial cell migration and proliferation. Certainly, cellular members of innate and adaptive immunity and their products can drive premalignancy into a malignant state by inducing chronic inflammation [4, 6] . Cancer cells also secret chemokines to attract host cells, which then supply the tumor with growth and angiogenic factors. CXC chemokines are known to play a pivotal role in the control of angiogenesis with CXCR4, the receptor for stromal cell-derived factor-1 (SDF-1)/CXCL12, being the first angiogenic chemokine receptor described on endothelial cells [7, 8] . Thus, not only are these chemokines recruiting cells into the tumor microenvironment, but they are also driving local angiogenesis. Hence, as intratumoral immune cells and tumor cells continue to secrete a range of cytokines and chemokines, tumor growth becomes inevitable and exponential. ulate vasculogenic processes from embryonic development and are capable of recruiting circulating precursor cells from the bone marrow into the tumor bed [9] . Bone marrow contribution to tumor vessels can rely on vascular integration of endothelial progenitor cells or on hematopoietic cell populations, which home specifically to tumors and contribute indirectly to neovascularization [10, 11] . The common theme is that tumorinfiltrating cells orchestrate the microenvironment and foster neovascularization directly or indirectly.
Two recent publications by Orimo et al. [12] and Spring et al. [13] describe fibroblasts and endothelial cells as components of the malignant stroma, which are capable of secreting inflammatory factors, which in turn, attract bone marrow-derived endothelial progenitor cells into the tumor environment. For instance, in human breast cancer tissue, secretion of SDF-1/CXCL12 by stromal fibroblasts recruits endothelial progenitors, which contribute substantially to tumor neovessels [12] . In transgenic mouse models of spontaneous tumor growth, we have demonstrated a tumor stage-dependent integration of bone marrow-derived progenitor cells, where only advanced tumors incorporate bone marrow precursors into the angiogenic vasculature [13] . It is striking that in murine hepatocellular carcinoma, this process is mediated by a group of CC chemokines such as CCL2, CCL3, and CCL5, which are released into the bloodstream in correlation with tumor size. It is important that these chemokines are produced exclusively by tumorresident endothelial cells and not by the tumor itself or tumorinfiltrating leukocytes. Moreover, the corresponding CC chemokine receptors CCR2 and CCR5 are expressed on tumor vessels as well as on circulating endothelial precursor cells. Therefore, increasing levels of CC chemokines foster neovascularization by stimulating vessel growth locally and by attracting progenitors from the bone marrow into the tumor bed. In this model, although tumors contain significant numbers of macrophages, lymphocyte migration is increasingly attenuated during tumor progression, concommittant with the expression of immunesuppressive cytokines by tumor endothelial cells [14] .
Other tumor types harbor infiltrating immune cells, which are "educated" in the tumor environment to facilitate angiogenesis and tumor progression. Recently, a distinct monocyte population of hematopoetic origin (tie-2-expressing monocytes) was discovered, which homes specifically to angiogenic sites and supports neovascularization indirectly in close association with endothelial cells [9 -11] . Myeloid Gr ϩ CD11b ϩ suppressor cells can increase dramatically at tumor sites and promote vasculogenesis by differentiating into endothelial cells, which incorporate into tumor endothelium [15] . It is interesting that there is mounting evidence that bone marrow-derived mononuclear cells can transdifferentiate into cells of various lineages, including endothelial cells [16, 17] . Hence, close vascular association or integration may not be mutually exclusive but a feature of the plasticity of tumor-infiltrating precursors and their potential to convert into a cell type, which is of high demand in the transforming tissue. This is supported by the description of a new leukocyte population coexpressing dendritic and endothelial cell markers in murine and human ovarian cancers. This population has the capacity to generate functional blood vessels in vivo in a sequence of events, where CCR6 ϩ dendritic cell precursors are attracted by tumoral ␤-defensins and subsequently, differentiate into endotheliallike cells in a VEGF high tumor environment [18] .
THE IMMUNE PARADOX
Inflammation creates a microenvironment, which potentiates neovascularization and the progression of cancer. It is important that manifestations of a distinct tumor environment can also impair immune effector function. For instance, tumorassociated macrophages, Gr ϩ CD11b ϩ myeloid cells, and dendritic cells experience a change in cytokine profile, which stimulates vessel sprouting and simultaneously down-regulates their antigen-presenting capacity [19 -23] . Moreover, in an environment of ongoing angiogenesis, the tumor vasculature changes profoundly and can attenuate lymphocyte infiltration into solid tumors [24, 25] .
These data imply that inflammation protects tumors from immune rejection. How then can we expect immunological cancer therapies to ever be effective? A prevalent view in tumor immunology is that a specific immune response, e.g., generation of tumor-specific CD4 ϩ and CD8 ϩ T cells, will confer protection against cancer growth. Although some success has been documented, primarily in subcutaneous tumor transplants [26] , this simplistic view neglects the fact that solid tumors are not just an accumulation of tumor cells but create their own local cytokine milieu and stromal components. Thus, the tumor microenvironment may prevent successfully activated lymphocytes to enter the tumor site or to function within it [25, 27] . Indeed, anticancer immune strategies, which focus on the induction of an adaptive immune response, are mainly effective in preclinical models in a prophylactic setting [28 -30] . In cancer patients, only sporadically induced tumor regression and sustained remission have been reported [31, 32] .
However, although chronic infections can foster carcinogenesis, certain infections and associated inflammatory responses are known to suppress tumor growth. For instance, microorganisms such as Listeria monocytogenes with anticancer activity have the capacity to elicit a strong cell-mediated Th1 immunity, which is accompanied by an inflammatory response involving cytokines such as IFN-␥ and IL-12. It is striking that they not only trigger cytotoxic T cell activity but also simultaneously block angiogenesis; this dual activity acts synergistically to suppress neoplastic growth [33] . Thus, it is not inflammation per se but inflammatory "context" that determines the ability of proinflammatory factors to facilitate or prevent neoplastic growth. The following paragraph summarizes results obtained in selected mouse models in which the inflammatory context was changed experimentally. Although a variety of molecules are capable of eliciting beneficial antitumor effects, our discussion focuses on the cytokines IL-12, IFN-␥, and IL-2, because of their well-documented, dual effects as proinflammatory and antiangiogenic factors.
INFLAMMATION-MEDIATED INHIBITION OF TUMOR ANGIOGENESIS
The prevailing role of IFN-␥ in modulating tumor stroma has been demonstrated in a series of experiments using IFN-␥
of endothelial cells into the tumor bed. This then interferes with neovascularization, resulting in tumor rejection [34 -36] . It is striking that the tumor stroma and not the tumor cells are the primary target of IFN-␥-producing T cells, although complete tumor rejection may involve direct tumor cell killing by antitumor lymphocytes and angiostatic effects. Table 1 shows a variety of experimental tumor models in which IFN-␥-mediated inhibition of angiogenesis during immune-mediated tumor rejection has been demonstrated.
Significant effort has focused on evaluating the efficacy of exogenous cytokines such as IL-12 and/or IL-2, administered systemically or locally into the tumor site with a major focus to enhance tumor-specific T cell recruitment and function (Table  1 ). It is surprising that a striking feature of these preclinical models is the interdependence of cytokine-driven innate immune responses, CD4 ϩ /CD8
ϩ T cell-mediated immunity, and antiangiogenic effects [28, 30, 37] . Systemic injection of IL-12 into transgenic mice predisposed for the development of mammary tumors inhibited tumor growth. Tumor inhibition was associated with deficient peri-and intratumoral angiogenesis, infiltration of effector cells, and the production of proinflammatory cytokines such as IL-1␤, IL-6, and the angiostatic CXC chemokines Mig/CXCL9 and IP-10/CXCL10 [28] . However, this treatment regimen was only effective in developing neoplastic lesions in a prophylactic setting. In a murine model of malignant mesothelioma (developed by exposing mice to asbestos fibers, excising tumors, and subcutaneously reinoculating cloned tumor cells), angiogenesis is an early event and coincides with the appearance of tumor-specific cytotoxic T cells in the tumor [30] . Nevertheless, tumors grow progressively. Repeated intratumoral injection of IL-2 significantly primed the endogenous, tumor-specific T cell response with CD4 ϩ and CD8 ϩ T cells being required for tumor rejection. It is interesting that tumor regression correlated with a reduction in blood vessels leading to and within the tumor, a process that mainly required functional CD8 ϩ lymphocytes. Here, IL-2 was sufficient for tumor rejection when relatively small, established tumors were treated but efficiency declined as tumor size increased [30] . These findings demonstrate that injection of IL-2 alone is capable of priming a local tumor-immune response, which also includes modulation of the tumor vasculature at an early stage during tumor progression. In contrast, a potent, therapeutic activity against established, spontaneous mammary carcinomas was induced when IL-12 and IL-2 were combined [37] . IL-12/pulse IL-2 combination therapy induced local T cell infiltration and induction of the IFN-␥-and TNF- a Incomplete list of immune therapies with combined immune and vascular effects, which lead to tumor rejection. Please note that most vascular changes are assessed by histological methods, which do not allow analysis of a three-dimensional vascular network. Mig, Monokine induced by IFN-␥; IP-10, IFN-inducible protein 10; EM, electron microscopy; EC, endothelial cell; RIPTag, rat insulin gene promoter II gene linked to the large T antigen of SV40; i.t., intratumorally; p.t., peritumorally; s.c., subcutaneously.
␣-inducible
These studies have shown that modification of the naturally occurring, intratumoral inflammation by injection of high doses of cytokines/chemokines can restore adaptive immunity, coinciding with reduced vascularity most likely induced by endothelial cell death (Table 1) . Strikingly different angiostatic effects were demonstrated in a transgenic mouse model of islet cell carcinogenesis. In this animal model, insulinomas develop through distinct stages as a consequence of expressing SV40 large T antigen in ␤ cells of the pancreas. Angiogenesis is an early event during tumor progression and creates a barrier for effector cell infiltration, resulting in the expansion of solid tumors devoid of infiltrating lymphocytes [24, 41] . Even adoptively transferred, antitumor effector cells fail to penetrate into the tumor tissue unless the tumor microenvironment has been "preconditioned." As intratumoral injection is not a practical option for endogenously growing tumors, a combination of irradiation and adoptive transfers of tumor-specific T cells triggered an inflammatory response at the tumor site. This treatment regimen resulted in complete regression of established, highly vascularized tumors over a period of weeks [39] . It is intriguing that irradiation "opened" solid tumors for effector cell infiltration, which coincided with conversion of the heterogeneous, tortuous tumor vasculature into a homogeneous network of capillaries, which resembled blood vessels of normal tissue. High intratumoral levels of IFN-␥ and secretion of the angiostatic chemokines Mig and IP-10 by infiltrating macrophages induced normalization of tumor vessels. Thus, in a more physiological setting, elevated expression of endogenous, antiangiogenic chemokines may change the dynamics of vessel growth rather than induce vessel death [42, 43] . Vascular remodeling was observed prior to complete tumor rejection, which most likely requires a combination of facilitated effector cell influx, reduced angiogenic activity, and direct tumor cell killing.
Again, these studies demonstrate the complex and intimate interaction among tumor-specific adoptive immunity, innate immune cells, and antiangiogenic effects. Moreover, they show the central role of the tumor stroma during tumor regression and the critical importance of the inflammatory context for an effective T cell response.
SHIFTING THE BALANCE FROM A PROANGIOGENIC TO AN ANTIANGIOGENIC, INFLAMMATORY ENVIRONMENT
An effective T cell response to tumors requires antigen presentation in tumor draining lymph nodes [44, 45] . However, for the ensuing effector phase, the tumor stroma is crucially important, as it influences the local priming of T cells [46] and lymphocyte access into tumor tissue [39, 47] and acts as direct target for immune destruction [34, 35] .
Blood vessels, as a major component of tumor stroma, have long been recognized as targets for cancer therapies. Although inducing tumor cell death simply by destroying tumor vasculature with antiangiogenic agents is an attractive concept [48] , reality shows that such treatment modalities are not powerful enough to induce complete tumor regression [49] . Given the intimate association of cytokine-induced alterations in the tumor microenvironment with leukocyte adhesion and angiogenesis (Table 1) , it seems more attractive to use the immune system itself to halt angiogenesis and boost tumor rejection. Most recent data from our lab show that the tumor stroma, in particular, vascular cells therein, display an amazing plasticity to accommodate a tumor's requirements [13] . Vice versa, these dynamic features can be exploited in a therapeutic setting to promote tumor rejection [30, 39, 47] (Fig. 1) . Therein, an antiangiogenic, proinflammatory environment reverses angiogenesis, activates endothelia, and facilitates effector cell penetration and antigen-specific tumor eradication. To date, however, "normalized" vessels are not well-characterized and although described as less tortuous, less dilated, and more hierarchically organized, further molecular and functional assays are needed to fully understand the nature of these changes [39] . Nevertheless, normalization of the vasculature must be a prerequisite to break the vicious cycle of tumor growth promotion and to optimize access of anticancer immune cells. We therefore propose that a successful immune-based anticancer strategy will use inflammatory factors, such as IFN-␥, which override the proangiogenic and immunosuppressive tumor environment by simultaneously enhancing adaptive and innate immune responses, as well as inducing secretion of antiangiogenic chemokines. If such an intratumoral "conditioning" is combined with classical immune-enhancing strategies, e.g., antitumor vaccination or adaptive T cell transfers, successful treatment of established tumors may ensue.
CONCLUDING REMARKS
It is now evident that cytokines and chemokines produced by stromal components such as inflammatory cells, fibroblasts, Fig. 1 . "Types" of intratumoral inflammation, which regulate tumor growth. Proinflammatory and proangiogenic factors foster neovascularization, immune suppression, and tumor growth. However, within this proinflammatory environment exists a potential antiangiogenic environment in which angiogenesis is reversible, promoting lymphocyte influx and immune-mediated tumor destruction.
and endothelial cells promote tumor angiogenesis and subvert immune cell function. Emerging data suggest that this process can be reversed, even in well-established, highly angiogenic tumors, by inducing the "right" inflammatory context. So far, most preclinical studies focus on subcutaneous transplantation tumors, which are easily accessible for manipulation. In these models, intratumoral injection of inflammatory factors is most effective when it activates tumor-resident stromal cells and immune effector cells. As most of the inflammatory mediators are toxic when applied systemically, a major advance will be to target the tumor environment of organ-specific cancers. An attractive strategy is to use tumor-specific vascular properties for the delivery of inflammatory compounds into the tumor bed. Genes and proteins, expressed by tumor resident endothelia but not normal counterparts, have been identified for some tumors [50 -53] . We expect that targeting antiangiogenic, proinflammatory cytokines into the tumor bed of an inaccessible, parenchymal tumor in combination with classical immuneenhancing strategies will overcome the tumor's intrinsic resistance to immune rejection.
